Key facts
- CoRegen’s last known valuation is $402.8M (May 2025).
- It has raised $121.4M across 1 recorded rounds; the latest was Early Stage VC ($13.5M) in Oct 2025.
- Notable investors include Kizoo Technology Capital.
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for CoRegen
Funding rounds
1 roundsAbout CoRegen
Developer of a drug discovery platform intended to accelerate the development of new cancer treatments. The company's platform utilizes machine learning to identify and rank therapeutic targets, refine and enhance drug candidates, and reprogram regulatory cells by modifying the steroid receptor coactivator gene, enabling researchers to create more precise and effective oncology therapies.
- Sector
- Healthcare
- HQ
- Houston, TX, United States
- Founded
- 2022
- Employees
- 9
- Website
- coregen.com/
- Ownership
- Privately Held (backing)
CoRegen doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CoRegen shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CoRegen in its N-PORT filings yet. We sweep new filings monthly.